The impact of single-dose trazodone administration on plasma endogenous adrenocorticotropic hormone and serum cortisol concentrations in healthy dogs.
anxiolytic
fear-free
hyperadrenocorticism
hypoadrenocorticism
hypothalamic-pituitary-adrenal axis
Journal
Journal of veterinary internal medicine
ISSN: 1939-1676
Titre abrégé: J Vet Intern Med
Pays: United States
ID NLM: 8708660
Informations de publication
Date de publication:
15 Nov 2023
15 Nov 2023
Historique:
received:
05
06
2023
accepted:
26
10
2023
medline:
15
11
2023
pubmed:
15
11
2023
entrez:
15
11
2023
Statut:
aheadofprint
Résumé
Conditions affecting the hypothalamic-pituitary-adrenal (HPA) axis are common in dogs. Testing the function of the HPA axis includes measurement of endogenous adrenocorticotropic hormone (eACTH) and performance of an adrenocorticotropic hormone (ACTH) stimulation test. Trazodone is commonly administered to dogs to decrease stress. In humans, trazodone significantly decreases plasma cortisol concentration via alpha-1 adrenergic activity. Determine the influence of trazodone on eACTH and serum cortisol concentrations in healthy dogs. Fourteen healthy, adult, companion dogs. Prospective, randomized placebo-controlled study. Trazodone (8-10 mg/kg) or placebo was administered PO 1 hour before eACTH measurement and ACTH stimulation testing. After a ≥7-day wash-out period, dogs received the opposite treatment. Differences in eACTH, pre- and post-ACTH stimulation cortisol concentrations, and delta (difference between pre- and post-ACTH) cortisol concentrations were analyzed using a paired t or signed-rank test with a P < .05 significance level. The eACTH concentrations were not significantly different (P = .23) between treatments. Similarly, no significant differences were found in the pre-ACTH cortisol concentrations between treatments (P = .40). Post-ACTH cortisol concentrations (P = .05) and delta cortisol concentrations (P = .04) were significantly lower when the dogs were treated with trazodone. Preliminary data suggest trazodone administration dampens the adrenocortical response to stimulation in healthy dogs. If similar effects are found in dogs with adrenal disease, the use of trazodone may affect diagnosis and clinical decision making in these populations.
Sections du résumé
BACKGROUND
BACKGROUND
Conditions affecting the hypothalamic-pituitary-adrenal (HPA) axis are common in dogs. Testing the function of the HPA axis includes measurement of endogenous adrenocorticotropic hormone (eACTH) and performance of an adrenocorticotropic hormone (ACTH) stimulation test. Trazodone is commonly administered to dogs to decrease stress. In humans, trazodone significantly decreases plasma cortisol concentration via alpha-1 adrenergic activity.
OBJECTIVES
OBJECTIVE
Determine the influence of trazodone on eACTH and serum cortisol concentrations in healthy dogs.
ANIMALS
METHODS
Fourteen healthy, adult, companion dogs.
METHODS
METHODS
Prospective, randomized placebo-controlled study. Trazodone (8-10 mg/kg) or placebo was administered PO 1 hour before eACTH measurement and ACTH stimulation testing. After a ≥7-day wash-out period, dogs received the opposite treatment. Differences in eACTH, pre- and post-ACTH stimulation cortisol concentrations, and delta (difference between pre- and post-ACTH) cortisol concentrations were analyzed using a paired t or signed-rank test with a P < .05 significance level.
RESULTS
RESULTS
The eACTH concentrations were not significantly different (P = .23) between treatments. Similarly, no significant differences were found in the pre-ACTH cortisol concentrations between treatments (P = .40). Post-ACTH cortisol concentrations (P = .05) and delta cortisol concentrations (P = .04) were significantly lower when the dogs were treated with trazodone.
CONCLUSIONS
CONCLUSIONS
Preliminary data suggest trazodone administration dampens the adrenocortical response to stimulation in healthy dogs. If similar effects are found in dogs with adrenal disease, the use of trazodone may affect diagnosis and clinical decision making in these populations.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : American Veterinary Medical Foundation and Veterinary Pharmacology Research Foundation
Informations de copyright
© 2023 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.
Références
Gruen ME, Roe SC, Griffith E, Hamilton A, Sherman BL. Use of trazodone to facilitate postsurgical confinement in dogs. J Am Vet Med Assoc. 2014;245:296-301.
Abrams J, Brennen R, Byosiere S-E. Trazodone as a mediator of transitional stress in a shelter: effects on illness, length of stay, and outcome. J Vet Behav. 2020;36:13-18.
Gruen ME, Sherman BL. Use of trazodone as an adjunctive agent in the treatment of canine anxiety disorders: 56 cases (1995-2007). J Am Vet Med Assoc. 2008;233:1902-1907.
Gilbert-Gregory SE, Stull JW, Rice MR, Herron ME. Effects of trazodone on behavioral signs of stress in hospitalized dogs. J Am Vet Med Assoc. 2016;249:1281-1291.
Chea B, Giorgi M. Trazodone: a review of its pharmacological properties and its off-label use in dogs and cats. Am J Anim Vet Sci. 2017;12:188-194.
Jay AR, Krotscheck U, Parsley E, et al. Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs. Am J Vet Res. 2013;74:1450-1456.
Arnold A, Davis A, Wismer T, Lee JA. Suspected hepatotoxicity secondary to trazodone therapy in a dog. J Vet Emerg Crit Care. 2021;31:112-116.
Behrend E, Kooistra H, Nelson R, et al. Diagnosis of spontaneous canine hyperadrenocorticism: 2012 ACVIM consensus statement (small animal). J Vet Intern Med. 2013;27:1292-1304.
Klein SC, Peterson ME. Canine hypoadrenocorticism: part I. Can Vet J. 2010;51:63-69.
Klein SC, Peterson ME. Canine hypoadrenocorticism: part II. Can Vet J. 2010;51:179-184.
Ambrogio AG, Pecori Giraldi F, Cavagnini F. Drugs and HPA axis. Pituitary. 2008;11:219-229.
Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr. 2009;14:536-546.
Fuller R. Serotonin receptors and neuroendocrine responses. Neuropsychopharmacology. 1990;3:495-502.
Monteleone P. Effects of trazodone on plasma cortisol in normal subjects. A study with drug plasma levels. Neuropsychopharmacology. 1991;5:61-64.
Catanese B, Lisciani R. Investigations on the absorption and distribution of trazodone or AF 1161 in rats, dogs and humans. Boll Chim Farm. 1970;109:369-373.
Aldridge C, Behrend E, Kemppainen R, et al. Comparison of 2 doses for ACTH stimulation testing in dogs suspected of or treated for hyperadrenocorticism. J Vet Intern Med. 2016;30:1637-1641.
Scott-Moncrieff JC, Koshko MA, Brown JA, Hill K, Refsal KR. Validation of a chemiluminescent enzyme immunometric assay for plasma adrenocorticotropic hormone in the dog. Vet Clin Pathol. 2003;32:180-187.
Reimers T, Salerno V, Lamb S. Validation and application of solid-phase chemiluminescent immunoassays for diagnosis of endocrine diseases in animals. Comp Haematol Int. 1996;6:170-175.
Louiset E, Duparc C, Lefebvre H. Role of serotonin in the paracrine control of adrenal steroidogenesis in physiological and pathophysiological conditions. Curr Opin Endocr Metab Res. 2019;8:50-59.
Feldman EC, Nelson RW, Reusch C, et al. Canine and Feline Endocrinology-e-Book. 4th ed. St. Louis, Missouri: Elsevier Health Sciences; 2015.
Martin LG, Groman RP, Fletcher DJ, et al. Pituitary-adrenal function in dogs with acute critical illness. J Am Vet Med Assoc. 2008;233:87-95.
Burkitt JM, Haskins SC, Nelson RW, Kass PH. Relative adrenal insufficiency in dogs with sepsis. J Vet Intern Med. 2007;21:226-231.
Oggianu L, Di Dato G, Mangano G, et al. Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations. Clin Transl Sci. 2022;15:1417-1429.